Tumour vasculature as a target for anticancer therapy

Cancer Treatment Reviews

Volumn 26, Issue 3, 2000, Pages 191-204

  Eatock, M M ^a   Schatzlein A ^a   Kaye, S B ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

Angiogenesis; Cancer therapy; Vascular targeting

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; ACIDIC FIBROBLAST GROWTH FACTOR; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; BATIMASTAT; COMBRETASTATIN; CYTOKINE; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; FIBRONECTIN; FUMAGILLOL CHLOROACETYLCARBAMATE; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MM 1270; MONOCLONAL ANTIBODY LM 609; PRINOMASTAT; PROTEINASE; SCLEROPROTEIN; THALIDOMIDE; TRIFLAVIN; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN; VITRONECTIN; WHI P 154;

CANCER; CELL INVASION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; REVIEW; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

EID: 0343673806     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.1999.0158     Document Type: Review

References (116)

1. Folkman J. Anti-angiogenesis: neconcept for therapy of solid tumours. Ann Surg. 175:1972;409-416
2. Folkman J. What is the evidence that tumours are angiogenesis dependent? JNCI. 82:1990;4-6
3. Gasparini G., Weidner N., Bevilaqua P., Maluta S., Dalla Palma P., Caffo O. Tumour microvessel density, p53 expression, tumour size and peritumoural lymphatic vessel invasion are relevant prognostic markers in node negative breast carcinoma. J Clin Oncol. 12:1994;454-466
4. Macchiarini P., Fontanini G., Hardin M. J., Squartini F., Angeletti C. A. Relation of neo-vascularisation to metastasis of non-small cell lung cancer. Lancet. 340:1992;145-146
5. Olvarez D., Ulbright T., DeReise W. Neovascularisation in clinical stage A testicular germ cell tumour: prediction of metastatic disease. Cancer Res. 54:1994;2800-2802
6. Srivastava S., Laidler P., Davies R. P., Horgan K., Hughes L. The prognostic significance of tumour vascularity in intermediate thickness (0.76-4.0 mm thick) skin melanoma. Am J Path. 133:1988;419-423
7. Weidner N., Carroll P. R., Flax J., Blumenfeld W., Folkman J. Tumour angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Path. 143:1993;401-409
8. Bicknell, R. Lewis, C. E. Ferrara, N. Tumour Angiogenesis, Oxford, Oxford University Press, 1997
9. Leek R. D., Lewis C. E., Whitehouse R., Greenall M., Clarke J., Harris A. L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast cancer. Cancer Res. 56:1996;4625-4629
10. Leung D. W., Cachiannes G., Kuang W-J., Goedell G. D., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309
11. Connolly D. T., Heuvelman D. M., Nelson R., Olander J. V., Eppley B. L., Delfino J. J. Tumour vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 84:1989;1470-1478
12. Philips G. D., Stone A. M., Jones B. D., Schultz J. C., Whitehead R. A. Vascular endothelial growth factor (rhVEGF 165) stimulates direct angiogenesis in the rabbit cornea. In Vivo. 8:1995;964-970
13. Pepper M. S., Montesano R. Proteolytic balance and capillary morphogenesis. Cell Different Devel. 32:1990;319-331
14. Rifkin D. B., Moscatelli D., Bizic J., Quarto N., Blei F., Dennis P. Growth factor control of extracellular proteolysis. Cell Different Devel. 32:1990;313-318
15. Tolnay E., Wiethege T., Kuhnen C., Wulf M., Voss B., Muller K. M. Expression of type IV collagenase correlates with the expression of vascular endothelial growth factor in primary non-small cell lung cancer. J Cancer Res Clin Oncol. 123:1997;652-658
16. Zucker S., Mirza H., Conner C. E. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer. 75:1998;780-786
17. Shweiki D. T., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia induced angiogenesis. Nature. 359:1992;843-845
18. Hyder S. M., Murthy L., Stancel G. M. Progestin regulation of vascular endothelial growth factor in human breast cancer cells. Cancer Res. 58:1998;392-395
19. Joseph I., Nelson J. B., Denmeade S. R., Isaacs J. T. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res. 3:1997;2507-2511
20. Scott P. A. E., Gleadle J. M., Bicknell R., Harris A. L. Role of the hypoxia sensing system, acidity and reproductive hormones in the variability of vascular endothelial growth factor induction in human breast carcinoma cell lines. Int J Cancer. 75:1998;706-712
21. Takahashi Y., Bucana C. D., Cleary K. R., Ellis L. M. p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer. 79:1998;34-38
22. Crew J. P., O'Brien T., Bradburn M. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 57:1997;5281-5285
23. Hartenbach E. M., Olson T. A., Goswitz J. J. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial overian carcinomas. Cancer Letters. 121:1997;169-175
24. Heits F., Katschinski D. M., Wiedemann G. J., Weiss C., Jelkmann W. Serum vascular endothelial growth factor (VEGF), a prognostic indicator in sarcoma and carcinoma patients. Int J Oncol. 10:1997;333-337
25. Maeda K., Chung Y. S., Ogawa Y. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br J Cancer. 73:1996;884-888
26. Mattern J., Koomagi R., Volm M. Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas. Int J Oncol. 6:1995;1059-1062
27. Okita S., Kondoh S., Shiraishi K., Kaino S., Hatano S., Okita K. Expression of vascular endothelial growth factor correlates with tumor progression in gallbladder cancer. Int J Oncol. 12:1998;1013-1018
28. Salven P., Maenpaa H., Orpana A., Alitalo K., Joensuu H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res. 3:1997a;647-651
29. Warren R. S., Yuan H., Matli M. R., Gillett N. A., Ferrarra N. Regulation by vascular endothelial growth factor expression of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest. 95:1995;1789-1797
30. Borgstrom P., Bourdon M. A., Hillan K. J., Sriramarao P., Ferrara N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate. 35:1998;1-10
31. Moscatelli D., Presta M., Rifkin D. B. Purification of a factor from human placenta that stimulates capillary endothelial cell protease production. Proc Natl Acad Sci USA. 83:1986;2091-2095
32. Gospodarowic D., Neufeld G., Schweigerer L. Fibroblast growth factor: structural and biological properties. J Cell Physiol Suppl. 5:1987;15-26
33. Goto F., Goto K., Weindel K., Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest. 69:1993;508-517
34. Ishikawa F., Miyazono K., Hellman U., Drexler H., Wernstedt C., Hagiwara K. Identification of angiogenic acivity and the cloning and expression of platelet derived endothelial cell growth factor. Nature. 338:1989;557-562
35. Haraguchi M., Miyadera K., Uemura K., Sumizawa T., Furukawa T., Yamada K. Angiogenic activity of enzymes. Nature. 368:1994;198
36. Fox S. B., Westwood M., Moghaddam A. The angiogenic factor platelet-dervied endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer. 73:1996;275-280
37. Giatromanolaki A., Koukourakis M. I., Kakolyris S. Focal expression of thymidine phosphorylase associates with CD31 positive lymphocytic aggregation and local neo-angiogenesis in non-small cell lung cancer. Anticancer Res. 18:1998;71-76
38. Igarashi M., Dhar D. K., Kubota H., Yamamoto A., El-Assal O., Nagasue N. The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus. Cancer. 82:1998;1225-1232
39. Maeda K., Kang S. M., Ogawa M. Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma. Int J Cancer. 74:1997;545-550
40. O'Brien T. S., Fox S. B., Dickinson A. J. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res. 56:1996;4799-4804
41. Tanigawa N., Amaya H., Matsumura M. Tumor angiogenesis and expression of thymidine phosphorylase/ platelet derived endothelial cell growth factor in human gastric carcinoma. Cancer Letters. 108:1996;281-290
42. Toi M., Hoshina S., Taniguchi T., Yamamoto Y., Ishitsuka H., Tominaga T. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int J Cancer. 64:1995;79-82
43. Amaya H., Tanigawa N., Lu C. Association of vascular endothelial growth factor expression with tumorangiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Letters. 119:1997;227-235
44. Engels K., Fox S. B., Whitehouse R. M., Gatter K. C., Harris A. L. Up-regulation of thymidine phosphorylase expressio n is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast. J Path. 182:1997;414-420
45. 3for angiogenesis. Science. 264:1994;569-571
46. Friedlander M., Brooks P. C., Shaffer R. W., Kincaid C. M., Varner J. A., Cheresh D. A. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 270:1995;1500-1502
47. 3to adhere to lymph node vitronectin. J Clin Invest. 90:1992;1406-1413
48. 3inegrin in human melanoma cell invasion. Proc Natl Acad Sci USA. 89:1992;1557-1561
49. 5monoclonal antibodies. J Cell Science 105:1993;101-111
50. Brooks P. C., Klemke R. L., Schon S., Lewis J. M., Schwartz M. A., Cheresh D. A. Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. J Clin Invest. 99:1997;1390-1398
51. Brooks P. C., Silletti S., von Schalscha T. L., Friedlander M., Cheresh D. A. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell. 92:1998;391-400
52. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 12:1996;697-715
53. Pasqualini R., Koivunen E., Ruoslahti E. alpha v Integrins as receptors for tumor targeting by circulating ligands. Nature Biotech. 15:1997;542-546
54. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:1998;377-380
55. Rabb H., Barroso-Vicens E., Adams R., Pow-Sang J., Ramirez G. Alpha-V/beta-3 and alpha-V/beta-5 integrin distribution in neoplastic kidney. Am J Nephrol. 16:1996;402-408
56. Max R., Gerritsen R., Nooijen P. Immunohistochemical analysis of integrin alpha v beta 3 expression on tumor-associated vessels of human carcinomas. Int J Cancer. 71:1997;320-324
57. Dirix L. Y., Vermeulen P. B., Pawinski A. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer. 76:1997;238-243
58. Dosquet C., Coudert M. C., Lepage E., Cabane J., Richard F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res. 3:1997;2451-2458
59. Salven P., Ruotsalainen T., Mattson K., Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer. 79:1998;144-146
60. Salven P., Teerenhovi L., Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood. 90:1997b;3167-3172
61. Kopec J. A., Abrahamowicz M., Easdaile J. M. Randomised discontinuation trials; utility and efficiency. J Clin Epidemiol. 46:1993;959-971
62. Kuasaka M., Sudo K., Matsutani E. Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-470). Br J Cancer. 69:1994;212-216
63. Antoine N., Greimers R., De Roanne C. AGM-470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res. 54:1994;2073-2076
64. Abe J., Zou W., Takuwa N. Fumagillin derivative angiogenesis inhibitor, AGM-470, inhibits the activation of cyclin dependent kinases and phosphorylation of retinoblastoma gene product but not tyrosyl phosphorylation or proto-oncogene expression in endothelial cells. Cancer Res. 54:1994;3407-3412
65. Bernsen H. J., Rijken P. F., Peters H., Bakker H., van der Kogel A. J. The effect of the anti-angiogenic agent TNP-470 on tumor growth and vascularity in low passaged xenografts of human gliomas in nude mice. J Neuro-Oncol. 38:1998;51-57
66. Futami H., Iseki H., Egawa S., Koyama K., Yamaguchi K. Inhibition of lymphatic metastasis in a syngeneic rat fibrosarcoma model by an angiogenesis inhibitor, AGM-1470. Invasion, Metastasis. 16:1996;73-82
67. Ikebe T., Yamamoto T., Kubo S. Suppressive effect of the angiogenesis inhibitor TNP-470 on the development of carcinogen-induced hepatic nodules in rats. Jap J Cancer Res. 89:1998;143-149
68. Kanai T., Konno H., Tanaka T. Effect of angiogenesis inhibitor TNP-470 on the progression of human gastric cancer xenotransplanted into nude mice. Int J Cancer. 71:1997;838-841
69. Miki T., Nonomura N., Nozawa M. Angiogenesis inhibitor TNP-470 inhibits growth and metastasis of a hormone-independent rat prostatic carcinoma cell line [see comments]. J Urol. 160:1998;210-213
70. Morita T., Shinohara N., Tokue A. Antitumour effect of a-synthetic analogue of fumagillin on murine renal carcinoma. Br J Urol. 74:1994;416-421
71. Sasaki A., Alcalde R. E., Nishiyama A. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption. Cancer Res. 58:1998;462-467
72. Yamaoka M., Yamamoto T., Masaki T., Ikeyama S., Sudo K., Fujita T. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470). Cancer Res. 53:1993;4262-4267
73. Yoshida T., Kaneko Y., Tsukamoto A., Han K., Ichinose M., Kimura S. Suppression of hepatoma growth and angiogenesis by a fumagillin derivative TNP470: possible involvement of nitric oxide synthase. Cancer Res. 58:1998;3751-3756
74. Dezube B. J., Von Roenn J. H., Holden-Wiltse J. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol. 16:1998;1444-1449
75. Kudelka A. P., Verschraegen C. F., Loyer E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470 [letter]. New Engl J Med. 338:1998;991-992
76. Watts M. E., Woodcock M., Arnold S., Chaplin D. J. Effects of novel and conventional anti-cancer agents on human endothelial permeability: influence of tumour secreted factors. Anticancer Res. 17:1997;71-75
77. Dark G. G., Hill S. A., Prise V. E., Tozer G. M., Pettit G. R., Chaplin D. J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature. Cancer Res. 57:1997;1829-1834
78. Beauregard D. A., Thelwall P. E., Chaplin D. J., Hill S. A., Adams G. E., Brindle K. M. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer. 77:1998;1761-1767
79. Drake C. J., Cheresh D. A., Little C. D. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Science 108:1995;2655-2661
80. Brooks P. C., Stromblad S., Klemke R., Visscher D., Sarkar F. H., Cheresh D. A. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin [see comments]. J Clin Invest. 96:1995;1815-1822
81. Mitjans F., Sander D., Adan J. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Science 108:1995;2825-2838
82. Sheu J. R., Yen M. H., Kan Y. C., Hung W. C., Chang P. T., Luk H. N. Inhibition of angiogenesis in vitro and in vivo: comparison of the relative activities of triflavin, an Arg-Gly-Asp-containing peptide and anti-alpha(v)beta3 integrin monoclonal antibody. Biochem Biophys Acta. 1336:1997;445-454
83. Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H., Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58:1998;1048-1051
84. Nguyen M., Arkell J., Jackson C. J. Active and tissue inhibitor of matrix metalloproteinase-free gelatinase B accumulates within human microvascular endothelial vesicles. J Biol Chem. 273:1998;5400-5404
85. Taraboletti G., Garofalo A., Belotti D. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. JNCI. 87:1995;293-298
86. Valente P., Fassina G., Melchiori A. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer. 75:1998;246-253
87. Sledge G. W. Jr, Qulali M., Goulet R., Bone E. A., Fife R. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. JNCI. 87:1995;1546-1550
88. Watson S. A., Morris T. M., Robinson G., Crimmin M. J., Brown P. D., Hardcastle J. D. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res. 55:1995;3629-3633
89. Nemunaitis J., Poole C., Primrose J. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res. 4:1998;1101-1109
90. Wojtowicz-Praga S., Torri J., Johnson M. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol. 16:1998;2150-2156
91. Jones P. H., Elliot M., Dobbs N. Phase I/II study of combination anti-angiogenesis therapy with marimastat, captopril and fragmin. Br J Cancer. 80 (Suppl 2):1999;3
92. Webber M. M., Waghray A. Urokinase mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid. Clin Cancer Res. 1:1995;755-761
93. Narla R. K., Liu X. P., Klis D., Uckun F. M. Inhibition of human glioblastoma cell adhesion and invasion by 4-(4′-hydroxylphenyl)-amino-6, 7-dimethoxyquniazoline (WHI-P131) and 4-(3′-bromo-4′-hydroxylphenyl)-amino-6, 7-dimehtoxy quinazo line (WHI-P154). Clin Cancer Res. 4:1998;3331-3338
94. Mishima T., Murata J., Toyoshima M. Inhibition of tumour invasion and metastasis by calcium spirulan (Ca-SP), a novel sulfated polysaccharide derived from a blue-green alga, Spirulina platensis. Clin Experiment Met. 16:1998;541-550
95. Gerber H. P., McMurtrey A., Kowalski J. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 273:1998;30336-30343
96. Wu H. M., Yuan Y., Zawieja D. C., Tinsley J., Granger H. J. Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperpermeability. Am J Phys. 276:1999;535-542
97. Hiratsuka S., Minowa O., Kuno J., Noda T., Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA. 95:1998;9349-9354
98. Seetharam L., Gotoh N., Maru Y., Neufeld G., Yamaguchi S., Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene. 10:1995;135-147
99. Olofsson B., Korpelainen E., Pepper M. S. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA. 95:1998;11709-11714
100. Fong T. A., Shawver L. K., Sun L. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:1999;99-106
101. D'Amato R. J., Loughnan M. S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 91:1978;4082-4085
102. Marx G. M., Levi J. A., Bell D. R. A phase I/II trial of thalidomide as an anti-angiogenic agent in the treatment of advanced cancer. Proc Am Soc Clin Oncol. 18:1999;1751
103. O'Reilly M. S. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. Exs. 79:1997;273-294
104. O'Reilly M. S., Boehm T., Shing Y. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277-285
105. Dhanabal M., Ramchandran R., Waterman M. J. Endostatin: induces endothelial cell apoptosis. J Biol Chem. 274:1999;11721-11726
106. Kakej Y., Teicher B. A. Pre-clinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Inv New Drugs. 15:1997;39-48
107. Herbst R. S., Takeuchi H., Teicher B. A. Paclitaxel/carboplatih administration along with an triangiogenic therapy in non-small cell lung and breast carcinoma models. Cancer Chemother Pharmacol. 41:1998;497-504
108. Belotti D., Vergani V., Borsotti P. The microtubule affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 2:1996;1843-1849
109. O'Leary J. J., Shapiro R. L., Ren C. J., Chuang N., Cohen H. W., Potmesil M. Antiangiogenic effects of camopthecin analogues 9-amino-20(S)-campothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res. 5:1999;181-187
110. Cassidy J., Duncan R., Morrison G. J. Activity of N-(2-hydroxypropyl) mathecrylamide copolymers containing daunomycin against a rat tumour model. Biochem Pharmacol. 38:1989;875-879
111. Steyger P. S., Baban D. F., Brereton M., Ulbrich K., Seymour L. W. Intratumoral distribution as a determinant of tumor responsiveness to therapy using polymer-based macromolecular prodrugs. J Contr Rel. 39:1996;35-46
112. Vasey P. A., Kaye S. B., Morrison R. Phase I clinical and pharmacokinetic study of PK1 (HPMA Co-polymer doxorubicin): first member of a new class of chemotherapeutic agents. Clin Cancer Res. 5:1999;83-94
113. Stastny M., Rihova B., Strohalm J., Ulbrich K. Comparison of the binding-kinetics of antibody-targeted n-(2-hydroxypropyl) methacrylamide (hpma)-bound doxorubicin in-vitro and in-vivo. J Contr Rel. 42:1996;229-236
114. 3during angiogenesis. J Clin Invest. 98:1996;426-433
115. Buckley C. D., Pilling D., Henriquez N. V. RGD peptides induce apoptosis by direct caspase-3 activation. Nature. 397:1999;534-539
116. Cao Y., O'Reilly M. S., Marshall B., Flynn E., Ji R. W., Folkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest. 101:1998;1055-1063